Dual expression of α-tocopherol-associated protein and estrogen receptor in normal/benign human breast luminal cells and the downregulation of α-tocopherol-associated protein in estrogen-receptor-positive breast carcinomas

Modern Pathology

Volumn 22, Issue 6, 2009, Pages 770-775

  Johnykutty, Sharlin ^a   Tang, Ping ^a   Zhao, Hongwei ^b   Hicks, David G ^a   Yeh, Shuyuan ^c   Wang, Xi ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Breast cancer; ER; TAP

Indexed keywords

ALPHA TOCOPHEROL; ESTROGEN RECEPTOR;

ARTICLE; BREAST CARCINOMA; BREAST DISEASE; BREAST EPITHELIUM; CANCER GRADING; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE ACTIVATION; GENE INACTIVATION; HORMONAL CARCINOGENESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INVASIVE CARCINOMA; MUTATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; TUMOR BIOPSY;

BREAST NEOPLASMS; CARCINOMA; CARRIER PROTEINS; DOWN-REGULATION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOPROTEINS; RECEPTORS, ESTROGEN; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 67349255703     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.24     Document Type: Article

References (19)

1. Platet N, Cathiard AM, Gleizes M, et al. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 2004;51:55-67.
2. Sorlie T. Molecular classification of breast tumors: toward improved diagnostics and treatments. Methods Mol Biol 2007;360:91-114.
3. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14:1368-1376.
4. Nielsen TO, Hsu FD, Jensen K, et al. Immunohisto-chemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374.
5. Shoker BS, Jarvis C, Clarke RB, et al. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 1999;155:1811-1815.
6. Henderson BE, Feigelson HS. Hormonal carcino-genesis. Carcinogenesis 2000;21:427-433.
7. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003;21:292-300.
8. Osborne C, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist 2004;9:361-377.
9. Kobayashi S. Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. Breast Cancer 2008;15:153-158.
10. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer 2008;15:303-308.
11. Moy B, Goss PE. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res 2006;12:4790-4793.
12. Wang X, Jing N, Hsu C-L, et al. Reduced expression of tocopherol-associated protein (TAP/Sec14L2) in human breast cancer. Cancer Invest 2009 (in press).
13. Tang P, Wang X, Schiffhauer L, et al. Expression patterns of ER-alpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ. Ann Clin Lab Sci 2006;36:137-143.
14. Kim MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-over-expressing phenotypes. Hum Pathol 2006;37:1217-1226.
15. Taylor-Papadimitriou J, Lane EB, Neville MC. The Mammary Gland: Development, Regulation and Function. Plenum: New York, 1987, pp 181-215.
16. Clarke RB. Human breast cell proliferation and its relationship to steroid receptor expression. Climacteric 2004;7:129-137.
17. Russo J, Ao X, Grill C, et al. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 1999;53:217-227.
18. Dey A, Verma CS, Lane DP. Updates on p53: modulation of p53 degradation as a therapeutic approach. Br J Cancer 2008;98:4-8.
19. Ni J, Wen X, Yao J, et al. Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway. Cancer Res 2005;65:9807-9816.